{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=16", "query": { "condition": "Carcinoma of the Bladder", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1037, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T06:43:10.885Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01215877", "title": "Tesetaxel for Previously Treated Patients With Bladder Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Transitional Cell" ], "interventions": [ { "name": "Tesetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genta Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2010-09", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-07-11", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 2, "location_summary": "New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01215877" }, { "nct_id": "NCT05562791", "title": "A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "[68Ga]PSMA", "type": "DRUG" }, { "name": "PET/CT imaging", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-09-28", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05562791" }, { "nct_id": "NCT06580002", "title": "Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Sarcoma", "Gastric Cancer", "Lung Cancer", "Head and Neck Cancer", "Colorectal Cancer", "Ovarian Cancer", "Liver Cancer", "Genitourinary Cancer", "Gynecologic Cancer", "Urinary Bladder Cancer", "Leukemia", "Lymphoid Leukemia", "Myeloma Multiple", "Prostate Cancer", "Pancreas Cancer", "Non-hodgkin Lymphoma", "Hodgkin Lymphoma", "Brain Cancer", "Melanoma", "Mycosis Fungoides", "Kidney Cancer" ], "interventions": [ { "name": "Riluzole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2024-12-02", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06580002" }, { "nct_id": "NCT06891209", "title": "Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Carcinoma" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-01-15", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06891209" }, { "nct_id": "NCT04254107", "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Carcinoma", "Gastroesophageal Junction Carcinoma", "Classical Hodgkin Lymphoma", "Diffuse Large B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Cutaneous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Bladder Cancer", "Ovarian Cancer", "Triple Negative Breast Cancer", "Cervical Cancer" ], "interventions": [ { "name": "SEA-TGT", "type": "DRUG" }, { "name": "sasanlimab", "type": "DRUG" }, { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2020-05-29", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04254107" }, { "nct_id": "NCT04306900", "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "TTX-030, budigalimab and mFOLFOX6", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, budigalimab and docetaxel", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and mFOLFOX6", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and budigalimab", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, nab-paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Budigalimab and mFOLFOX6", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Trishula Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 185, "start_date": "2020-03-30", "completion_date": "2024-03-27", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 26, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04306900" }, { "nct_id": "NCT06682728", "title": "Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Muscle-invasive Bladder Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan (SG)", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2024-11-15", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06682728" }, { "nct_id": "NCT07514143", "title": "Bladder EpiCheck Product Development Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Suspicion of Bladder Cancer", "NMIBC Surveillance" ], "interventions": [ { "name": "Bladder EpiCheck", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Nucleix Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 1000, "start_date": "2025-09-15", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 2, "location_summary": "San Diego, California • Towson, Maryland", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Towson", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07514143" }, { "nct_id": "NCT04200963", "title": "A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Urothelial Carcinoma Bladder", "Bladder Cancer", "Bladder Disease", "Solid Tumor", "Solid Carcinoma", "Solid Tumor, Adult", "Metastatic Cancer", "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Bladder Cancer", "Metastatic Urothelial Carcinoma", "Locally Advanced Solid Tumor", "Neoplasms", "Neoplasm Metastasis", "Neoplasm Malignant", "Neoplasm, Bladder", "Urothelial Neoplasm", "Neoplasm, Urinary Bladder", "Bladder Neoplasm", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "IK-175", "type": "DRUG" }, { "name": "IK-175 and nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-12-18", "completion_date": "2023-07-18", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04200963" }, { "nct_id": "NCT02903914", "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumors", "Colorectal Cancer (CRC)", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Renal Cell Carcinoma (RCC)", "Bladder Cancer", "UC (Urothelial Cancer)", "Mesothelioma" ], "interventions": [ { "name": "INCB001158", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2016-09-14", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-15T06:43:10.885Z", "location_count": 13, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903914" } ] }